EPCAM and neoplasm: Vorobyeva et al. evaluated, in a preclinical setting, the PET imaging potential of the EpCAM-binding DARPin Ec1 conjugated to [125I]I-PIB in a human ovarian cancer xenograft model and observed a tumor-to-blood ratio of 19 at 6 h post-injection, which increased to 31 at 24 h post-injection, thereby providing high-contrast tumor localization [38].